

Marian Ludgate

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5954088/publications.pdf>

Version: 2024-02-01

73
papers

2,920
citations

236925

25
h-index

175258

52
g-index

77
all docs

77
docs citations

77
times ranked

3306
citing authors

#	ARTICLE	IF	CITATIONS
1	Editorial: Mechanisms and Novel Therapies in Gravesâ€™ Orbitopathy: Current Update. <i>Frontiers in Endocrinology</i> , 2022, 13, 902591.	3.5	0
2	Modulating gut microbiota in a mouse model of Gravesâ€™ orbitopathy and its impact on induced disease. <i>Microbiome</i> , 2021, 9, 45.	11.1	41
3	Oxidative Stress-Induced Sirtuin1 Downregulation Correlates to HIF-1 α , GLUT-1, and VEGF-A Upregulation in Th1 Autoimmune Hashimotoâ€™s Thyroiditis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3806.	4.1	14
4	The Role of Mitochondria-Linked Fatty-Acid Uptake-Driven Adipogenesis in Graves Orbitopathy. <i>Endocrinology</i> , 2021, 162, .	2.8	2
5	Expression of Endogenous Putative TSH Binding Protein in Orbit. <i>Current Issues in Molecular Biology</i> , 2021, 43, 1794-1804.	2.4	4
6	Orbital Signaling in Gravesâ€™ Orbitopathy. <i>Frontiers in Endocrinology</i> , 2021, 12, 739994.	3.5	6
7	DNA methylation at a nutritionally sensitive region of the <i>PAX8</i> gene is associated with thyroid volume and function in Gambian children. <i>Science Advances</i> , 2021, 7, eabj1561.	10.3	13
8	Controlled Antenatal Thyroid Screening II: Effect of Treating Maternal Suboptimal Thyroid Function on Child Behavior. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e417-e427.	3.6	32
9	New insights into the pathogenesis and nonsurgical management of Graves orbitopathy. <i>Nature Reviews Endocrinology</i> , 2020, 16, 104-116.	9.6	155
10	Fibrosis in dysthyroid eye disease. <i>Eye</i> , 2020, 34, 279-284.	2.1	5
11	Distinctive Features of Orbital Adipose Tissue (OAT) in Gravesâ€™ Orbitopathy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9145.	4.1	9
12	Shining a light on thyroid eye disease. <i>Nature Reviews Endocrinology</i> , 2020, 16, 259-260.	9.6	3
13	Microbiome and Gravesâ€™ Orbitopathy. <i>European Thyroid Journal</i> , 2020, 9, 78-86.	2.4	14
14	Role of Hyaluronan in Human Adipogenesis: Evidence from in-Vitro and in-Vivo Studies. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2675.	4.1	4
15	Prostaglandin F2-Alpha Eye Drops (Bimatoprost) in Graves' Orbitopathy: A Randomized Controlled Double-Masked Crossover Trial (BIMA Trial). <i>Thyroid</i> , 2019, 29, 563-572.	4.5	11
16	Cambridge Ophthalmological Symposium 2018: introduction and reflections on the day. <i>Eye</i> , 2019, 33, 169-173.	2.1	0
17	Controlled Antenatal Thyroid Screening II: Effect of Treating Maternal Suboptimal Thyroid Function on Child Cognition. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1583-1591.	3.6	79
18	Combining micro-RNA and protein sequencing to detect robust biomarkers for Gravesâ€™ disease and orbitopathy. <i>Scientific Reports</i> , 2018, 8, 8386.	3.3	33

#	ARTICLE	IF	CITATIONS
19	Gut microbiota in experimental murine model of Graves' orbitopathy established in different environments may modulate clinical presentation of disease. <i>Microbiome</i> , 2018, 6, 97.	11.1	65
20	Gut Microbiome in BALB/c and C57BL/6J Mice Undergoing Experimental Thyroid Autoimmunity Associate with Differences in Immunological Responses and Thyroid Function. <i>Hormone and Metabolic Research</i> , 2018, 50, 932-941.	1.5	39
21	The microbiota and autoimmunity: Their role in thyroid autoimmune diseases. <i>Clinical Immunology</i> , 2017, 183, 63-74.	3.2	91
22	Meeting abstracts from the 64th British Thyroid Association Annual Meeting. <i>Thyroid Research</i> , 2017, 10, .	1.5	2
23	The Role of Thyrotropin Receptor Activation in Adipogenesis and Modulation of Fat Phenotype. <i>Frontiers in Endocrinology</i> , 2017, 8, 83.	3.5	27
24	Thyroid eye disease- an update. <i>Expert Review of Ophthalmology</i> , 2016, 11, 273-284.	0.6	14
25	The sodium iodide symporter is unlikely to be a thyroid/breast shared antigen. <i>Journal of Endocrinological Investigation</i> , 2016, 39, 323-331.	3.3	7
26	Characterisation of adipocyte-derived extracellular vesicles released pre- and post-adipogenesis. <i>Journal of Extracellular Vesicles</i> , 2015, 4, 29159.	12.2	88
27	Future Research in Graves' Orbitopathy: From Priority Setting to Trial Design Through Patient and Public Involvement. <i>Thyroid</i> , 2015, 25, 1181-1184.	4.5	8
28	The second wave of the Controlled Antenatal Thyroid Screening (CATS II) study: the cognitive assessment protocol. <i>BMC Endocrine Disorders</i> , 2014, 14, 95.	2.2	20
29	Effects of Prostaglandin F ₂ ± on Adipocyte Biology Relevant to Graves' Orbitopathy. <i>Thyroid</i> , 2013, 23, 1600-1608.	4.5	24
30	Adipose Tissue Depot-Specific Differences in the Regulation of Hyaluronan Production of Relevance to Graves' Orbitopathy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 653-662.	3.6	64
31	Association of FOXE1 Polyalanine Repeat Region with Papillary Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E1814-E1819.	3.6	52
32	Comparative proteomic analysis to dissect differences in signal transduction in activating TSH receptor mutations in the thyroid. <i>International Journal of Biochemistry and Cell Biology</i> , 2012, 44, 290-301.	2.8	10
33	Metabolic syndrome: is the preadipocyte to blame?*. <i>Clinical Endocrinology</i> , 2012, 76, 19-20.	2.4	2
34	Effect of iodine on early stage thyroid autonomy. <i>Genomics</i> , 2011, 97, 94-100.	2.9	15
35	Brown fat and obesity: the next big thing?. <i>Clinical Endocrinology</i> , 2011, 74, 661-670.	2.4	57
36	Pathogenesis of Graves Orbitopathy. <i>Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry</i> , 2011, 11, 72-82.	0.5	3

#	ARTICLE	IF	CITATIONS
37	Extrathyroidal thyroid hormone synthesis?. Journal of Endocrinology, 2011, 210, 3-4.	2.6	4
38	Transient congenital hypothyroidism due to thyroid-stimulating hormone receptor blocking antibodies: a case series. Annals of Clinical Biochemistry, 2011, 48, 386-390.	1.6	23
39	TSH receptor activation and body composition. Journal of Endocrinology, 2010, 204, 13-20.	2.6	44
40	Metformin Reduces Arterial Stiffness and Improves Endothelial Function in Young Women with Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled, Crossover Trial. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 722-730.	3.6	133
41	Effects of Dehydroepiandrosterone Replacement on Vascular Function in Primary and Secondary Adrenal Insufficiency: A Randomized Crossover Trial. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1966-1972.	3.6	39
42	GsI± signalling suppresses PPARÎ³2 generation and inhibits 3T3L1 adipogenesis. Journal of Endocrinology, 2009, 202, 207-215.	2.6	25
43	Thyrotropin Receptor Activation Increases Hyaluronan Production in Preadipocyte Fibroblasts. Journal of Biological Chemistry, 2009, 284, 26447-26455.	3.4	73
44	Metamorphic Thyroid Autoimmunity. Thyroid, 2008, 18, 1035-1037.	4.5	28
45	Modulation of expression of somatostatin receptor subtypes in Gravesâ€™ ophthalmopathy orbits: relevance to novel analogs. American Journal of Physiology - Endocrinology and Metabolism, 2007, 293, E1630-E1635.	3.5	9
46	W546X mutation of the thyrotropin receptor causes subclinical hypothyroidism in various clinical settings. Clinical Endocrinology, 2007, 67, 317-319.	2.4	1
47	Animal Models of Autoimmune Thyroid Disease. , 2007, , 79-93.		6
48	Biological Effects of Thyrotropin Receptor Activation on Human Orbital Preadipocytes. , 2006, 47, 5197.		72
49	Altered Tear Composition in Smokers and Patients With Graves Ophthalmopathy. JAMA Ophthalmology, 2006, 124, 1451.	2.4	39
50	Reevaluating Thyrotropin Receptor-Induced Mouse Models of Gravesâ€™ Disease and Ophthalmopathy. Endocrinology, 2005, 146, 835-844.	2.8	57
51	A Transgenic Mouse with a Deletion in the Collagenous Domain of Adiponectin Displays Elevated Circulating Adiponectin and Improved Insulin Sensitivity. Endocrinology, 2004, 145, 367-383.	2.8	480
52	Inducing Gravesâ€™ ophthalmopathy. Journal of Endocrinological Investigation, 2004, 27, 211-215.	3.3	29
53	Early Changes in Thyroid-Stimulating Antibody Activity following Radioiodine Therapy. Medical Principles and Practice, 2003, 12, 266-268.	2.4	3
54	Production and Application of Polyclonal Antibody to Human Thyroid Transcription Factor 2 Reveals Thyroid Transcription Factor 2 Protein Expression in Adult Thyroid and Hair Follicles and Prepubertal Testis. Thyroid, 2003, 13, 927-932.	4.5	22

#	ARTICLE	IF	CITATIONS
55	Peroxisome Proliferator-Activated Receptor- β in Thyroid Eye Disease: Contraindication for Thiazolidinedione Use?. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 55-59.	3.6	90
56	Animal Models of Thyroid-Associated Ophthalmopathy. Thyroid, 2002, 12, 205-208.	4.5	12
57	Demonstration of Immunoglobulin G, A, and E Autoantibodies to the Human Thyrotropin Receptor Using Flow Cytometry. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 1754-1761.	3.6	50
58	Mutation of the gene encoding human TTF-2 associated with thyroid agenesis, cleft palate and choanal atresia. Nature Genetics, 1998, 19, 399-401.	21.4	378
59	The Thyrotropin Receptor in Thyroid Diseases. New England Journal of Medicine, 1997, 337, 1675-1681.	27.0	237
60	APOPTOSIS IN AUTOIMMUNE AND NON-AUTOIMMUNE THYROID DISEASE. , 1997, 182, 123-124.		13
61	Patient with monoclonal gammopathy, thyrotoxicosis, pretibial myxedema and thyroid-associated ophthalmopathy; demonstration of direct binding of autoantibodies to the thyrotropin receptor. European Journal of Endocrinology, 1996, 134, 97-103.	3.7	21
62	Controlled Antenatal Thyroid Screening Study; Obstetric Outcomes. Endocrine Abstracts, 0, , .	0.0	4
63	The randomised probiotic trial of indigo study (investigation of novel biomarkers and definition of) Tj ETQq1 1 0.784314 rgBT ₃ /Overlo	0.0	
64	Development of an inductively coupled plasma-mass spectrometry method for measurement of urine iodine and assessment of iodine status in subclinical hypothyroidism. Endocrine Abstracts, 0, , 1-1.	0.0	0
65	The Thr92Ala substitution in deiodonase-2 is associated with increased odds of a sub-optimal IQ score in children with low-normal thyroid function. Endocrine Abstracts, 0, , .	0.0	0
66	Adverse metabolic correlations relate to free T3 levels in subclinical hypothyroidism; common FOXE1 polymorphisms associate with blood pressure. Endocrine Abstracts, 0, , .	0.0	0
67	TSH and free-T3 correlate negatively and independently with bone mineral density in adults with subclinical hypothyroidism. Endocrine Abstracts, 0, , .	0.0	0
68	Immune reaction to food antigens in Graves'disease (GD) patients: role of gliadin and other food antigens. Endocrine Abstracts, 0, , .	0.0	0
69	Autoantibodies to the thyrotropin receptor in Alemtuzumab-induced thyroid autoimmunity: determination of their biological activity, and possible role as predictive marker of disease. Endocrine Abstracts, 0, , .	0.0	0
70	Detecting blood micro-RNAs and proteins associated with Graves' disease and orbitopathy. Endocrine Abstracts, 0, , .	0.0	0
71	Controlled Antenatal Thyroid Screening (CATS) II: long-term cardiometabolic effects of treating maternal sub-optimal thyroid function. Endocrine Abstracts, 0, , .	0.0	0
72	Novel insights into the genetic architecture of thyroid disease. Endocrine Abstracts, 0, , .	0.0	0

#	ARTICLE	IF	CITATIONS
73	Long-term cardiometabolic effects of maternal sub-optimal gestational thyroid function and relative treatment in the Controlled Antenatal Thyroid Screening (CATS) study II. Endocrine Abstracts, 0, , .	0.0	0